Monsanto's Guidance Keeps Growing

Recs

2

Disney Buys Marvel!

...And David Gardner called it. He's up 1,334%! See what David's recommending that you buy NEXT!

Click here now to find out!

It seems like Monsanto's (NYSE: MON) changes in financial guidance have come so regularly this year that you can set your clock to them. Today, we got another one, which fortunately continued the upward trend.

Technically, Monsanto actually lowered guidance, but that's because its previous forecast didn't include charges for in-process research and development from its acquisition of vegetable-seed producer De Ruiter. Excluding those charges, a one-time payment from its spinoff Solutia (NYSE: SOA), and income from Posilac, the cow hormone Monsanto sold to Eli Lilly (NYSE: LLY), adjusted guidance rose to $3.58 to $3.60 per share, from previous guidance of $3.37 per share.

It seems rather odd that the company is increasing the range of its guidance as it gets closer to the end of its fiscal year. Still, will investors really complain about an 80% increase in ongoing EPS?

The increase mostly comes from better-than-expected seed sales. Monsanto expects to make $100 million more off sales of its seeds this fiscal year -- putting it 25% ahead of last year. There's no slowdown in sight for the seed business, either; Monsanto is hoping for 25% to 30% increase in gross profit from its corn seed sales next year.

I like seeing Monsanto increasing the profits coming from seeds, rather than its herbicide Roundup, because the latter has a definitive cap on its growth. Just like fertilizer producers Agrium (NYSE: AGU) and PotashCorp (NYSE: POT) are limited by the number of acres farmers plant, sales of Roundup can only grow so much until further growth is tied directly to the price of commodities.

Seeds, on the other hand, have comparatively unlimited growth potential. By increasing the yield of the seeds, Monsanto can charge more, even if no additional acres are planted. The fact that Monsanto is selling more seed than expected is a good sign that it's taking market share from competitors Syngenta (NYSE: SYT) and DuPont (NYSE: DD), thus increasing its competitive moat.

Closed for 15 months – opening 10 days only! Get notified ahead of time as our expert portfolio manager invests $1 MILLION in the best opportunities from across The Motley Fool’s premium investment services. This is the first open since August 2008, by invitation only. Enter email below.

What do you think of Monsanto's upgrade? Log in to CAPS, make an outperform or underperform pick, and tell us why in a pitch.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Eli Lilly is a Motley Fool Income Investor recommendation. The Fool has a disclosure policy.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On September 16, 2008, at 10:08 PM, wwmcn wrote:

    How do we know that Monsanto's increased income from seed sales were at the expense of SYT and DD? Not having seen your sources, my thought is that it is likely that the increases come from significant unit price increases and from increases overseas in areas adopting new technology. I think SYT and DD are seeing more new technology seed dollars too, also from price increases and overseas expansion.

  • Report this Comment On September 16, 2008, at 10:20 PM, wwmcn wrote:

    I have not seen your source information, however my thinking is that most of Monsanto's increased seed revenues were probably from significant price increases and increased sales overseas in areas adapting their new technologies. As to cutting into sales of SYT and DD, I expect they too have seen similar increases in sales revenue of seeds, from higher pricing of new technology seeds and from expansion overseas.

    So do we really know their sales really at the expense of SYT and DD?

Add your comment.

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 729191, ~/Articles/ArticleHandler.aspx, 11/8/2009 11:07:40 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

The Must-Read Story on Fool.com
Which Companies Can Buy It Like Buffett?

Related Tickers

11/6/2009 4:02 PM
AGU $50.11 Up +0.30 +0.60%
Agrium, Inc. (USA) CAPS Rating: *****
DD $33.38 Down +0.00 +0.00%
E.I. du Pont de Ne… CAPS Rating: ****
LLY $34.50 Up +0.07 +0.20%
Eli Lilly & Co. CAPS Rating: ****
MON $69.14 Down -0.32 -0.46%
Monsanto Company CAPS Rating: ****
POT $96.25 Up +0.60 +0.63%
Potash Corp./Saska… CAPS Rating: ****
SYT $50.85 Up +0.64 +1.27%
Syngenta AG (ADR) CAPS Rating: *****

Community: Investing Wiki

Term Of The Hour

Par value: Par value is the carrying value of stock on the company's books. It usually ranges from a dollar down to a few pennies (or less) and sometimes is listed at zero.

Want to learn more or edit this definition?
Click here to read more!